New imaging agent predicts early metabolic response to HER2-targeted therapy in metas

[News]

A new imaging agent, 68Ga-ABY-025, can predict early metabolic response to human epidermal growth factor receptor 2 (HER2)-targeted treatment in HER2-positive metastatic breast cancer patients, according to new research published in the September issue of The Journal of Nuclear Medicine.

More... (https://www.news-medical.net/news/20230927/New-imaging-agent-predicts-early-metabolic-response-to-HER2-targeted-therapy-in-metastatic-breast-cancer.aspx)